文献速递前列腺增生与排尿功能障碍泌尿系感染

COVID-19是良性前列腺增生进展及相关症状加重的危险因素吗?系统综述

Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-05-18

该系统性综述探讨SARS-CoV-2靶向前列腺并加重良性前列腺增生(BPH)症状及并发症的潜在机制。检索截至2021年4月,纳入52篇文献。结果显示SARS-CoV-2可能通过ACE2信号、雄激素受体相关机制、炎症和代谢紊乱损伤前列腺,加重BPH及下尿路症状(LUTS)。

要点

  • SARS-CoV-2通过结合ACE2感染宿主细胞,可能损伤前列腺。
  • 感染期间RAS系统过度激活可激活促炎通路,加重LUTS。
  • 雄激素受体参与BPH病理生理,SARS-CoV-2感染可能为雄激素介导。

核心结论

  • SARS-CoV-2可能通过ACE2信号、AR相关机制、炎症和代谢紊乱损伤前列腺,加重BPH及相关LUTS。

研究设计与样本

  • 系统综述,检索截至2021年4月,数据库包括PubMed、Embase、Web of Science、Scopus和Cochrane Library,遵循PRISMA指南,采用PICO策略。
  • 最终纳入52篇文献,均为人类研究且以英文发表。

主要发现

  • SARS-CoV-2通过结合ACE2感染宿主细胞。
  • 感染期间RAS系统过度激活可能导致促炎通路激活和细胞因子释放增加。
  • 病毒可加重LUTS并触发前列腺炎症过程。
  • AR在BPH病理生理中起重要作用,SARS-CoV-2感染可能为雄激素介导,BPH进展及相关症状可能是COVID-19通过AR参与和代谢紊乱引发的并发症。

临床怎么用

  • 建议未来研究探究COVID-19在BPH相关LUTS进展中的可能作用。
  • 对易感患者可用IPSS问卷和PSA等血清生物标志物评估前列腺状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To explore the potential mechanisms of SARS-CoV-2 in targeting the prostate gland, leading to exacerbation of benign prostatic hyperplasia (BPH) symptoms and greater risks of BPH complications such as acute urinary retention. METHODS: A categorized and comprehensive search in the literature has been conducted by 10 April 2021 using international databases including PubMed, Embase, Web of Science, Scopus, and Cochrane Library in line with the PRISMA guidelines recommendations. PICO strategy was used to formulate the research question. The following terms were used: urology, COVID-19, coronavirus, BPH, inflammation, androgen receptors, LUTS, IPSS, PSA, and SARS-CoV-2 or a combination of them. Studies with irrelevant purposes and duplicates were excluded. The selected studies were performed on humans and published in English. RESULTS: The research revealed 89 articles. After title screening and considering exclusion criteria, 52 papers were included for the systematic review. BPH is a common condition affecting older men. SARS-CoV-2 infects the host cell by binding to angiotensin converting enzyme 2 (ACE2). A hyperactivated RAS system during infection with SARS-CoV-2 may lead to activation of pro-inflammatory pathways and increased cytokine release. Thus, this virus can lead to exacerbation of lower urinary tract symptoms (LUTS) and trigger inflammatory processes in the prostate gland. Since androgen receptors (AR) play an important role in the BPH pathophysiology and infection with SARS-CoV-2 may be androgen-mediated, BPH progression and its related symptoms can be a complication of COVID-19 through AR involvement and metabolic disturbances. CONCLUSIONS: Based on the current findings, SARS-CoV-2 can possibly damage the prostate and worsen BPH and its related LUTS through ACE2 signaling, AR-related mechanisms, inflammation, and metabolic derangement. We encourage future studies to investigate the possible role of COVID-19 in the progression of BPH-related LUTS and examine the prostatic status in susceptible patients with relevant available questionnaires (e.g., IPSS) and serum biomarkers (e.g., PSA).

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Haghpanah A, Masjedi F, Salehipour M, et al. Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review. Prostate Cancer Prostatic Dis. 2021. PMID: 34007019. doi:10.1038/s41391-021-00388-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。